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background: There are limited data evaluating benefits of everolimus-eluting stents (EES) over first-generation drug-eluting stents (1st-gen DES) 
in diabetic patients with multivessel disease.
Methods: The study cohort included 429 consecutive diabetic patients who underwent native multivessel PCI defined as ≥2 same-generation DES 
in at least two different native vessel territories during the same index procedure. Patients with significant left main disease or with a history of prior 
bypass were excluded. The primary safety end point was the combined incidence of death, non-fatal Q-wave myocardial infarction and definite stent 
thrombosis.
results: At 1 year, the primary end point was reached in 2.9% of the EES patients, which was significantly lower than the 9.3% (p=0.03) noted with 
1st-gen DES. The occurrence of definite or probable stent thrombosis was lower in the EES group (3.7% vs. 0%, p=0.04). Similarly, there was a trend 
toward lower all-cause mortality (2.9% vs. 8.5%, p=0.05) and cardiac death (1% vs. 4.9%, p=0.08) in the EES group. In a multivariate model, EES 
was independently associated with lower risk of composite primary end point compared to 1st-gen DES [HR: 0.28 (95% CI 0.09-0.94)].
conclusions: In diabetic patients undergoing native multiveesel PCI, the use of EES was associated with superior 1-year safety compared 1st-gen 
DES. This benefit was mainly driven by decreased rate of all-cause mortality in the EES group.
One year outcomes
Outcome Everolimus-eluting Stent(n= 105) First-generation DES(n= 324) p value
Primary safety end point 3(2.9%) 30(9.3%) 0.03
Death 3(2.9%) 27(8.5%) 0.05
Cardiac death 1(1%) 16(4.9%) 0.08
Death/QWMI 3(2.9%) 30(9.4%) 0.03
Myocardial infarction 4(3.9%) 10(3.3%) 0.76
Target lesion revascularization 13(12.6%) 29(9.3%) 0.33
Target vessel revascularization 15(14.6%) 45(14.4%) 0.96
Definite or probable stent thrombosis 0% 12(3.7%) 0.04
Definite stent thrombosis 0% 7(2.2%) 0.20
